Microbot Medical Launches LIBERTY Robotic System, First Hospital Adoption Announced
- First Hospital Adoption: Emory University Hospital becomes the first to adopt the LIBERTY robotic system, marking a significant advancement in its application for peripheral vascular procedures and enhancing the hospital's leadership in interventional radiology.
- Market Release Plans: Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to accelerate market adoption through showcasing its innovative technology and driving growth in the medical robotics sector.
- Technological Innovation: LIBERTY is the world's first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions, aimed at improving procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing patient care quality.
- Strategic Collaboration: Microbot is collaborating with Emory University Hospital to establish an Endovascular Robotics Program, supporting clinicians in delivering precise care for procedures like liver tumor embolization, which further solidifies the company's strategic position in the medical robotics market.
Get Free Real-Time Notifications for Any Stock
Analyst Views on MBOT
About MBOT
About the author
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.
